Sanofi provides therapeutic solutions. It offers Cerezyme and Cerdelga for Gaucher disease, Myozyme and Lumizyme for Pompe disease, Fabrazyme for Fabry disease, and Aldurazyme for mucopolysaccharidosis Type 1; Aubagio, an immunomodulatory; and Lemtrada, a monoclonal antibody to treat multiple sclerosis. The company also provides Jevtana, a taxane derivative for prostate cancer; Taxotere, a taxoid for cancers; Eloxatin, an agent for colorectal cancer; Thymoglobulin, an immunosuppressive and immunomodulating agent; Mozobil, a hematopoietic stem cell mobilizer; and Zaltrap, a protein for metastatic colorectal cancer.
Read More…
Industry, Sector and Symbol
Industry Drug Manufacturers - Major
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone+33-1-53774000
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
EmployeesN/A
Next Earnings DateN/A
OptionableOptionable
Sanofi (EPA:SAN) Frequently Asked Questions
What is Sanofi's stock symbol?
Sanofi trades on the EPA under the ticker symbol "SAN."
What price target have analysts set for SAN?
15 Wall Street analysts have issued 12 month price targets for Sanofi's stock. Their predictions range from €79.00 to €100.00. On average, they anticipate Sanofi's stock price to reach €88.80 in the next year. This suggests a possible upside of 7.4% from the stock's current price. View Analyst Price Targets for Sanofi.
What is the consensus analysts' recommendation for Sanofi?
15 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Sanofi in the last year. There are currently 4 hold ratings and 11 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Sanofi.
Has Sanofi been receiving favorable news coverage?
Media coverage about SAN stock has been trending negative this week, InfoTrie Sentiment Analysis reports. The research group rates the sentiment of media coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Sanofi earned a coverage optimism score of -2.3 on InfoTrie's scale. They also gave headlines about the company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an impact on the company's share price in the immediate future. View News Stories for Sanofi.
Who are some of Sanofi's key competitors?
What other stocks do shareholders of Sanofi own?
Who are Sanofi's key executives?
Sanofi's management team includes the folowing people:
- Mr. Olivier Brandicourt, CEO & Director (Age 63)
- Mr. Jean-Baptiste Chasseloup de Chatillon, Exec. VP & CFO (Age 54)
- Mr. Laurent Gilhodes, Principal Accounting Officer and VP of Corp. Accounting
- Mr. Bruno Ménard, Chief Information officer
- Mr. George Grofik, Head of Investor Relations
What is Sanofi's stock price today?
One share of SAN stock can currently be purchased for approximately €82.68.
What is Sanofi's official website?
How can I contact Sanofi?
Sanofi's mailing address is 54 rue la Boetie, PARIS, 75008, France. The company can be reached via phone at +33-1-53774000.
MarketBeat Community Rating for Sanofi (EPA SAN)
MarketBeat's community ratings are surveys of what our community members think about Sanofi and other stocks. Vote "Outperform" if you believe SAN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SAN will underperform the S&P 500 over the long term. You may vote once every thirty days.
